At the close on September 22, 2026, Dexcom stock had opened at USD 89.17 while the Nasdaq Composite gained 0.45 percent to 27 ...

On May 29, Goldman Sachs analyst David Roman initiated coverage DexCom Inc. (NASDAQ:DXCM) with a Buy rating and a price target of $104. The initiation is part of Goldman Sachs’s broader coverage ...

Dexcom Inc. stock is trading around USD 89.60 on Nasdaq as of September 20, 2026, close to its 52-week high after a strong ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Will Abbott, which is expanding into comprehensive healthcare centered on FreeStyle Libre, or DexCom, which is aiming for high growth and high profitability as a CGM specialist, prevail?]Record Date: ...

Mr. Sylvain joined Dexcom in 2018 and has served as Executive Vice President and Chief Financial Officer since 2021.

DXCM's strong growth, G7 15 Day adoption and CONNECT trial could expand its CGM market opportunity despite reimbursement and ...

Dexcom ( ) has issued an announcement. On September 10, 2026, Dexcom ’s board appointed Executive Vice President and Chief Financial Officer Jereme Sylvain to the expanded role ...

DexCom, Inc. announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026. Mr. Boehnlein is a highly accomplished healthcare executive and finance leader with ...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2026 financial results after market close on Thursday, April 30, 2026. Management will ...

DexCom is leveraging AI to drive operational efficiency and product innovation, positioning itself as a platform medical provider in CGM. DXCM achieved 300 basis points in operating margin improvement ...

Dexcom has announced a new continuous glucose monitoring system designed for people using basal insulin, oral therapies or GLP-1 receptor agonists1. The new system will be available shortly.